Monday, November 5, 2012

FDA approves antidepressant Cymbalta for treatment of pain caused by diabetic peripheral neuropathy

Eli Lilly announced that the FDA has approved the antidepressant Cymbalta (duloxetine HCl; pronounced SIM-BALL-TA), judging it safe and effective for the management of diabetic peripheral neuropathic pain, a symptom of nerve damage that affects up to 5 million Americans.

Cymbalta, a balanced and potent serotonin and norepinephrine reuptake inhibitor, is the first and only FDA-approved treatment for pain caused by diabetic peripheral neuropathy. This approval came after a six-month priority review. More than 18 million Americans have diabetes and are at risk for developing persistent pain -- often described as burning, stabbing or shooting pain -- as a result of nerve damage believed to be caused by high blood sugar.

On August 3, the agency approved Cymbalta as a treatment for major depression in adults. It is available immediately by prescription in pharmacies across the United States for the treatment of major depression or pain associated with diabetic peripheral neuropathy.

Lilly proved Cymbalta's safety and efficacy in the treatment of pain caused by diabetic peripheral neuropathy at doses of 60 and 120 mg per day in two randomized, 12-week, double-blind, placebo-controlled, fixed-dose studies in non-depressed adults who had the disorder for at least 6 months. However, doses of 120 mg per day, although safe and effective, were not as well tolerated as 60 mg per day. On average, patients in the studies were 60 years old, suffered from diabetes for 11 years and from related diabetic neuropathy for four years, and at the beginning of the studies, rated their pain as moderate to moderately severe.

In both studies, Cymbalta significantly reduced 24-hour average pain, compared with placebo. Improvements were noted as early as the first week of treatment and continued for the duration of the studies. In addition, Cymbalta showed rapid onset of action and sustained effect in reducing pain caused by diabetic neuropathy at both 60 mg per day and 120 mg per day, and was effective in relieving pain at night. Nighttime pain is especially troublesome to many patients with diabetic neuropathy, because it can interfere with sleep.

"Until now, we didn't have a simple and effective therapy for patients living with diabetic neuropathic pain. Instead, we were left with medications that often required multiple dose adjustments, or for patients to take several pills throughout the day. This is difficult for many of these patients, as they already take a host of medications for their diabetes and other conditions, which can put them at increased risk for drug interactions and dose-limiting side effects," said Timothy Smith, M.D., R.Ph., Medical Director, Mercy Health Research, St. Louis, and a Cymbalta investigator. "With Cymbalta, we finally have a therapy proven to provide real relief for many of these patients, without the complicated dosing schedule."

Although Cymbalta does not change the underlying nerve damage caused by diabetic peripheral neuropathy, it does help relieve the stabbing, burning and shooting pain often associated with the disorder. Scientists believe it does this by increasing levels of serotonin and norepinephrine, two neurotransmitters, or chemical messengers, believed to be important in regulating a person's emotions as well as sensitivity to pain. Increasing these levels in a balanced way is thought to improve the body's natural ability to regulate pain.

"We know that Cymbalta as an antidepressant is effective at treating both the emotional and painful physical symptoms of depression," said Stephen Stahl, M.D., Ph.D., chairman of the Neuroscience Education Institute and adjunct professor of psychiatry at the University of California at San Diego School of Medicine. "Seeing significant benefit in diabetic neuropathic pain, among patients who did not have depression, helps confirm that this drug has a positive impact on pain that is separate from improvement in mood."
 I want to warn you about watching what you drink and other medicines you take. It turns out that even a little alcohol (3 drinks a month) and Motrin (6 pills taken over one week) will hurt your liver while on Cymbalta. I found this out through a routine blood test.
 Cymbalta has saved my life!! I have been on multiple antidepressants over the last 11 years. I have fibromyalgia/chronic fatigue immune deficiency disorder and if that's not enough to cause depression, I don't know what is!! pain 24/7...I have never felt better! I have been taking it for over a year now and it is still working wonderfully. I'm sorry for y'all's problems with it. but I have been very impressed with it


5 comments:

  1. diabetic neuropathic pain results from damage or disease affecting the somatosensory system.[1] It may be associated with abnormal sensations called dysesthesia, and pain produced by normally non-painful stimuli (allodynia).

    ReplyDelete
  2. Painful diabetic neuropathic pain is a common complication of diabetes and can affect many aspects of life and severely limit patients' daily functions.

    ReplyDelete
  3. Neurostim is one such simple product which can provide much relief and considered to be one of the best diabetic neuropathic pain relief products.

    ReplyDelete
  4. diabetic neuropathic pain can be classified as peripheral, autonomic, proximal, or focal. Each affects different parts of the body in various ways.

    ReplyDelete
  5. In diabetic neuropathic pain, Commonly used agents, including the recently approved duloxetine and pregabalin, are reviewed, and their effective dose ranges, titration schemes, contraindications, and recommended monitoring are discussed.

    ReplyDelete